The PPARβ/δ-specific activator GW501516 and shRNAs to decrease expression of PPARβ/δ, BCL-6, and MMP-9 were used in two human pancreatic cancer cell lines, Miapaca-2 (COX-2 negative) and BxPc-3 (COX-2 positive). Here, BCL6 is linked to pancreatic neoplasm.